Phibro Animal Health Corp: Form 10-Q for the period ended Mar 31, 2026
Filed with the SEC on May 6, 2026 and accepted by EDGAR at May 6, 2026, 20:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-01-01 to 2026-03-31 | $383.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2025-07-01 to 2026-03-31 | $1.12bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2026-01-01 to 2026-03-31 | $257.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2025-07-01 to 2026-03-31 | $743.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2026-01-01 to 2026-03-31 | $125.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-07-01 to 2026-03-31 | $378.1m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2026-01-01 to 2026-03-31 | $81.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2025-07-01 to 2026-03-31 | $231.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2026-01-01 to 2026-03-31 | $44.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-07-01 to 2026-03-31 | $146.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-01-01 to 2026-03-31 | $10.7m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2025-07-01 to 2026-03-31 | $35.7m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2026-01-01 to 2026-03-31 | $8.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-07-01 to 2026-03-31 | $27.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2026-01-01 to 2026-03-31 | $24.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-07-01 to 2026-03-31 | $78.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-01-01 to 2026-03-31 | $0.59 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-07-01 to 2026-03-31 | $1.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-01-01 to 2026-03-31 | $0.59 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-07-01 to 2026-03-31 | $1.92 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-01-01 to 2026-03-31 | 41,037,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-07-01 to 2026-03-31 | 40,956,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-07-01 to 2026-03-31 | $44.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-07-01 to 2026-03-31 | $40.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2025-07-01 to 2026-03-31 | $14.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2026-03-31 | $54.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-03-31 | $894.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-03-31 | $1.45bn | us-gaap:Assets |
| Current liabilities | At period end2026-03-31 | $281.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-03-31 | $1.08bn | us-gaap:Liabilities |
| Long-term debt | At period end2026-03-31 | $597.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2026-03-31 | $22.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2026-03-31 | $361.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-26-056280. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.